82P Stock Overview
Engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 82P from our risk checks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Pacira BioSciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$20.80 |
| 52 Week High | US$29.00 |
| 52 Week Low | US$10.70 |
| Beta | 0.56 |
| 1 Month Change | -4.59% |
| 3 Month Change | -19.38% |
| 1 Year Change | -26.24% |
| 3 Year Change | -64.75% |
| 5 Year Change | -46.39% |
| Change since IPO | 335.24% |
Recent News & Updates
Recent updates
Shareholder Returns
| 82P | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -4.6% | 2.2% | 1.4% |
| 1Y | -26.2% | -18.1% | 13.8% |
Return vs Industry: 82P underperformed the German Pharmaceuticals industry which returned -18.1% over the past year.
Return vs Market: 82P underperformed the German Market which returned 13.8% over the past year.
Price Volatility
| 82P volatility | |
|---|---|
| 82P Average Weekly Movement | 8.1% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 82P has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 82P's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 789 | Frank Lee | www.pacira.com |
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis.
Pacira BioSciences, Inc. Fundamentals Summary
| 82P fundamental statistics | |
|---|---|
| Market cap | €970.19m |
| Earnings (TTM) | -€92.88m |
| Revenue (TTM) | €629.26m |
1.6x
P/S Ratio-10.9x
P/E RatioIs 82P overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 82P income statement (TTM) | |
|---|---|
| Revenue | US$702.77m |
| Cost of Revenue | US$239.33m |
| Gross Profit | US$463.44m |
| Other Expenses | US$567.17m |
| Earnings | -US$103.73m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.24 |
| Gross Margin | 65.94% |
| Net Profit Margin | -14.76% |
| Debt/Equity Ratio | 73.1% |
How did 82P perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/14 01:17 |
| End of Day Share Price | 2025/05/14 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pacira BioSciences, Inc. is covered by 31 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anita Dushyanth | Berenberg |
| Gary Nachman | BMO Capital Markets Equity Research |
| Tazeen Ahmad | BofA Global Research |